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Abstract.  We have studied the interaction of 1251- 
antithrombin  (125I-AT) with microvascular endothelial 
cells (RFPEC) to localize the cellular site of an- 
ticoagulantly active heparan  sulfate proteoglycans 
(HSPG). The radiolabeled protease inhibitor bound 
specifically to the above HSPG with a Kd of ,'050 nM. 
Confluent monolayer RFPEC cultures exhibited a  lin- 
ear increase in the amount of AT bound per cell for 
up to  16 d,  whereas suspension RFPEC cultures pos- 
sessed a constant number of protease inhibitor binding 
sites per cell for up to 5 d.  These results suggest that 
monolayer RFPEC cultures secrete anticoagulantly ac- 
tive HSPG, which then accumulate in the extracellular 
matrix.  This hypothesis was confirmed by quantitative 
light and EM level autoradiography which demon- 
strated that the AT binding  sites are predominantly 1o- 
cated in the extracellular matrix with only small quan- 
tities of protease inhibitor complexed to the cell 
surface. 
We have also pinpointed the in vivo position of an- 
ticoagulantly active HSPG within the blood vessel 
wall.  Rat aortas were perfused, in situ,  with 125I-AT, 
and bound labeled protease inhibitor was localized by 
light and EM autoradiography.  The anticoagulantly ac- 
tive HSPG were concentrated immediately beneath the 
aortic and vasa vasorum endothelium with only a very 
small extent of labeling noted on the luminal  surface 
of the endothelial cells. Based upon the above data, 
we propose a model whereby luminal and abluminal 
anticoagulantly active HSPG regulate coagulation 
mechanism activity. 
T 
HE biologic activities of blood coagulation enzymes are 
regulated by protease inhibitors of the serpin super- 
family, particularly antithrombin  (AT). This protease 
inhibitor is a 58,000-kD protein that inactivates its target en- 
zymes, such as thrombin,  by forming covalent  complexes 
with them. Heparin binds AT, and induces a conformational 
change in the protein that augments the rate of formation  of 
enzyme-inhibitor complexes by several orders of magnitude 
(Rosenberg and Damus,  1973). 
Damus et al.  (1973) proposed that the non-thrombogenic 
properties of blood vessels are due,  in part,  to anticoagu- 
lantly active heparin-like  components on the luminal surface 
of endothelial  cells. This hypothesis is supported by several 
independent lines  of evidence.  Heparan sulfate  glycosami- 
noglycans  with  heparin-like  activity  have  been  extracted 
from bovine microvascular capillary endothelial  cells and 
from aortic endothelium (Marcum et al.  1983; Marcum and 
Rosenherg,  1984). Cultured cloned or noncloned bovine ma- 
1. Abbreviations  used in this paper: AT, antithrombin; HSPG, heparan sul- 
fate proteoglycans;  IMDM, Iscove's modified  Dulbecco's  media; RFPEC, 
rat epididymal fat pad endothelial cells; SVC, surface-connected vesicle. 
crovascular endothelial cells, and cultured cloned or noncloned 
rodent microvascular  endothelial  cells synthesize  a unique 
subset of anticoagulantly  active  heparan  sulfate proteogly- 
cans (HSPG) (1-10% of total HSPG) with glycosaminogly- 
can chains of appropriate  monosaccharide sequence to bind 
and activate AT (Marcum and Rosenberg, 1985; Marcum et 
al., 1986a,b). AT interacts with anticoagulantly active HSPG 
on freshly prepared bovine aortic segments  that possess a 
continuous layer of endothelial  cells as judged by scanning 
EM, and the complexed protease inhibitor rapidly neutral- 
izes added coagulation  enzymes (Stern et al.,  1985).  The 
perfusion of intact rat or mouse hindlimb  vasculature  with 
purified thrombin as well as AT leads to a 20-fold enhanced 
rate of formation  of coagulation  enzyme-protease inhibitor 
complexes.  This acceleratory phenomena is caused by anti- 
coagulantly  active HSPG since the effect can be eliminated 
by prior infusion with purified Flavobacterium heparinase. 
The rare heparin-containing  mast cells associated with the 
perfused blood vessels play no role in the above events since 
the same experimental findings are observed with mice that 
are genetically  deficient  in this  cell type (Marcum et al., 
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vivo, are endowed with anticoagulantly active HSPG whose 
glycosaminoglycan  chains would interact with blood AT, and 
thereby regulate the activity of the coagulation system. 
The potential abluminal position of these potent anticoag- 
ulant substances has been assessed indirectly both in vivo 
and in vitro. Carlson and co-workers have infused AT into 
rabbit and humans and have observed a three-compartment 
distribution of the protease inhibitor between plasma, the 
vessel wall and an extravascular compartment (Carlson et 
al.,  1984,  1985).  Hatton and collaborators used intact as 
well as deendothelialized rabbit aorta segments to study AT 
binding to the vascular endothelium and to the subendothe- 
lial basement membrane. (Hatton et al., 1986, 1988). Flavo- 
bacterium heparitinase treatment of the exposed subendo- 
thelium reduced the AT binding and also seemed to deplete 
the subendothelium of small proteoglycan-rich granules and 
basement membrane, as shown by transmission EM. 
We have attempted to visualize the position of the an- 
ticoagulantly active HSPG in cultured rat microvascular en- 
dothelial cells as well as in the intact rat aorta by examining 
the binding of ~25I-AT with light and EM level autoradiogra- 
phy. This subset of proteoglycans bear carbohydrate chains 
with  regions  of defined  monosaccharide  sequence.  Our 
results indicate that small amounts of the anticoagulantly ac- 
tive HSPG are present on the luminal surface of cultured en- 
dothelial cells as well as blood vessels but that much larger 
quantities of  anticoagulantly  active proteoglycan are found in 
the extracellular matrix as well as bound to the abluminal 
cell membrane of blood vessels. Based upon these data, we 
propose  that both  luminal and abluminal  sources  of an- 
ticoagulantly active HSPG may regulate coagulation system 
activity under different conditions. 
Materials and Methods 
Materials 
Purified human AT was purchased from Cutter Biological (Berkley,  CA). 
Flavobacterium  heparitinase was purified as previously described (Marcum 
et ai., 1984).  Chondroitinase ABC and dextran sulfate were obtained from 
Sigma Chemical Co. (St. Louis, MO). Sodium beparin from porcine intesti- 
nal mucosa was provided by Diosynth, Inc. (Chicago, IL). 
Cells in Culture 
Microvascular endothelial cells were originally isolated from rat epididymal 
fat pad, and then cloned from single cells as previously described (Marcum 
and Rosenberg, 1985).  These cloned cells spontaneously transformed into 
a stable cell line that was used for this study (RFPEC). Monolayer cultures 
were grown in M199 medium containing 10%  FCS (Gibeo Laboratories, 
Grand Island, NY),  100 U/ml penicillin, and 100 #g/ml of streptomycin 
in a 5% CO2, 95% air-humidified atmosphere at 370C. Cells in suspension 
were cultured in S-MEM (Joklik modified) medium (Gibco Laboratories) 
containing 20%  FCS,  100  U/ml penicillin, 100/~g/ml streptomycin, 1% 
BME 100x vitamins (Sigma Chemical Co.), amino acids at the concentra- 
tion used in standard M199 medium, and 1.06 g/liter Phironic F68 (BASF 
Wyandotte Corp., Wyandotte, M1).  The cells were grown in siliconized 
glass Erlenmeyer flasks, and kept under constant rotatory agitation on a 
shaker at 250 rpm for up to 5 d at 37°C. Chinese hamster ovary cells were 
a  gift from M.  Krieger (Massachusetts Institute of Technology). Bovine 
smooth muscle cells were isolated by enzymatic dispersion of bovine aortic 
media (Fritze et ai.,  1985). 
Isolated Rat Aorta 
Male Sprague-Dawley rats (300-400 g) were anesthetized by intramuscular 
injection of 80 nag of Nembutal (sodium pentabarbitol)/kg animal weight. 
The arterial and venous trunks were carefully exposed, and then detached 
from the underlying tissue. All lumbar veins, as well as the inferior vena 
cava and dorsal aorta at the renal veins, and the common iliac artery were 
ligated.  A  20  gauge  butterfly  needle was  flushed,  filled with  Iscove's 
modified Dulbecco's media 0MDM) (Gibco Laboratories), inserted into 
the dorsal aorta just above the branch of the common iliac artery, and held 
in place with a double ligature. The dorsal aorta and inferior vena cava were 
missioned just beneath the ligature,  and  the aorta gently flushed with 
IMDM. The ligatures surrounding the lumbar veins and common iliac ar- 
tery  were cut,  and the blood vessel preparation removed. For study of 
damaged aorta, the vessel was crushed repeatedly along its length with a 
pair of hemostats after dissection and following flushing with IMDM to re- 
move the blood. 
The aortic preparation was washed for 15 min with IMDM media con- 
taining 50/~g/ml BSA and 1% Nutridoma SP (Boehringer Mannlaeim Bio- 
chemicals, Indianapolis, IN) until the perfusate was clear. At this point, 
3 ml of 125I-AT (5-10 nM 125I-AT, 2--4  x  107 cpm]ntl), or Iz~I-BSA (6 nlvi 
125I-BSA, 3  x  107 cpm/ml) was refluxed through the aorta, for either 1 or 
3 h at a flow rate of 30 ml/h. These conditions were judged to be adequate 
with respect to oxygen and nutrient supply as evidenced by the clear main- 
tainance of cellular integrity at the EM level. Oxygenation of the perfusate 
was achieved by bubbling air from a pasteur pipette every 1-2 min. As a 
further  negative  control  vessels were  perfused  for  1  h  with  purified 
Flavobacterium  heparitinase at a final concentration of 89 nM to remove 
heparan sulfates, washed for 30 rain with IMDM containing 50 #g/ml BSA 
and 1% Nutridoma SP and then perfused with 125I-AT as described above. 
After perfusion, free or loosely bound radioactive protein was removed by 
washing for 30 min with IMDM at a flow rate of 60 rnl/h (which was found 
to cause no mechanical damage to the endothelium [Fig. 6 A]). The prepara- 
tion was then perfused with fixative (2.5% glutaraldehyde in PBS) for 1 h 
before immersion in fixative for an additional hour. The dorsal aorta was 
then dissected from the preparation and cross-sectioned into small ring- 
shaped pieces for subsequent embedment and microscopic examination. 
Iodination of  Proteins 
AT was labeled with 125I-NaI (15  mCi/t~g,  Amersham Corp., Arlington 
Heights, IL), using the chloramine T method (Greenwood et al., 1963).  To 
protect the beparin binding site of the protease inhibitor during the labeling 
procedure, AT was iodinated in the presence of a  10-fold molar excess of 
affinity-fractionated  beparin octasaccharide (Atha et al., 1987). Heparin oc- 
tasaccharide was subsequently separated from *~I-AT by gel filtration on 
a  Seph~dex G-75  (Pharmacia Fine Chemicals, Piscataway,  NI)  column 
equilibrated in 50 mM sodium phosphate, pH 7.2 containing 1 M  NaC1. 
Radiolabeled protcase inhibitor was then desalted by gel filtration on a 
Sephadex G-25 column equilibrated in 50 mM sodium phosphate, pH 7.2 
containing 0.15 M NaC1, and 20 t~g/rnl BSA. The 12SI-AT  had a specific ac- 
tivity of 8  x  104 cprn/ng, and was able to bind with avidity to high- 
molecular weight heparin (data not shown). For control experiments, BSA 
was  iodinated by  the above method to  a  specific activity of 7  x  104 
cpm/ng. 
Binding of ~I-AT to Endothelial Cells in Culture 
Cells in Monolayer.  The binding assay on monolayer cultures was per- 
formed on cells grown in 96-well microtiter plates for 7 d or more. The cells 
reached confluence after 3-5 d. Cell monolayers were pre-incubated for 
1 h at 37°C with media containing 1% Nutridoma SP rather than serum, 
to eliminate serum-borne AT. The cells were then incubated with 125I-AT 
diluted in PBS containing 1% Nntridorna SP and 50/~g/ml BSA, with or 
without a  100-fold  excess of unlabeled AT for 1 h at 40C.  The unbound 
ligand was eliminated by washing five times with PBS containing 100/~g/rnl 
BSA, and the cells were removed from the wells by using cotton swabs. The 
swabs were then counted in a gamma counter (LKB Instruments, Gaithers- 
burg, MD). Cell numbers were estimated by trypsinizing control wells, and 
then counting cells on a  Coulter counter (Coulter Electronics, Hialeah, 
FL). All determinations were preformed in triplicate. 
Cells in Suspension. Cells grown in suspension were harvested by cen- 
trifngation (800 g,  1 min), and then resuspended in PBS containing 1% 
Nutridoma SP and 50/~g/ml BSA. Roughly 0.5-1  x  106 cells were in- 
cubated in siliconized Eppendorf tubes with 0.2 ml of I~I-AT with or with- 
out competing unlabeled AT for 1 h at 37°C with agitation. After eliminat- 
ing free or loosely bound ligand by washing four times with 1 mi of PBS 
containing 100/~g/ml BSA, the bound labeled protease inhibitor, and the 
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formed in duplicate. 
The values of bound ~25I-AT were normalized for 50,000 cells, and non- 
specific binding was subtracted. Nonspecitic binding was assessed by resid- 
ual complexed counts in the presence of a 100-fold excess of unlabeled AT, 
and accounted for 25-30%  of the total bound counts. 
Preparation of Cells for Microscopic Examination. The cell mono- 
layers and cell suspensions were prepared for microscopic examination by 
incubating the cells as described above for 2 h (monolayers) or 1 h (suspen- 
sion cultures) with 5-10 nM 1251-AT (2--4 x  107 cpm]ml), or 6 nM I~I-BSA 
(3  ×  107 cpm/mi) at 4°C, washing the cells as outlined above, and then 
fixing them as described below. 
Preparation of  Cells and 1Issue  for Light and 
Electron Microscopy 
All fixation steps were carded out with 2.5% glutaraldehyde in PBS for 
1 h at 4°C. Cell suspensions and cell monolayers were processed differently 
because suspension cells were pelleted (800 g  for 5 min) before fixation, 
whereas monolayer cells are fixed directly on the dish. After fixation, the 
cells were washed three times in Sabatini's solution (PBS with 6.8 % su- 
crose). At this point, the cell pellets were cut into small (1 mm  3) cubes. All 
samples were then postfixed with 1% osmium tetroxide for an additional 
hour,  followed by three washes in Sabatini's solution. The samples were 
passed through a graded series of alcohols (30,  50, 75, 90, and 100%  for 
15  min each), followed by treatment with propylene oxide (15  rain) for 
pellets (Epon-EtOH for monolayers), a 1:1 Epon-propylene oxide mix (1 h), 
and three changes in pure Epon (3  h,  3  h,  and overnight). Samples of 
monolayers suitable for sectioning were prepared by inverting Beem cap- 
sules full of resin directly onto the dish. Cell pellet samples were prepared 
by embedment in Ladd embedding trays.  Samples of aorta were oriented 
in transverse section in Beem capsules full of resin. Polymerization was at 
64°C overnight. After embedment, monolayer samples could be snapped 
off the dish, and cut en face; pelleted cells and aorta may be cut directly. 
Semithin (250 nm) sections, slightly oblique to the plane of the dish from 
monolayer cell preparations or transverse sections of aorta,  were cut for 
light-microscopic autoradiography. The obliquity of the section plane al- 
lowed cells from all levels within the culture to be examined in the same 
section. A microtome (Ultracut; Reichert Scientific Instruments, Buffalo, 
NY) with a sapphire knife (LKB Instruments) was used, allowing very large 
(6 mm) sections to be cut. Sections were dried on glass slides, stained with 
toluidine blue, and dried. 
Serial ultrathin (60 nm) sections, true to the plane of the dish, were cut 
from monolayer samples, from cell pellets, and from selected regions of the 
aorta for EM. Similar non-serial sections, with no defined orientation, were 
cut from pelleted samples. All sections for EM were cut with a microtome 
(MT2; Sorvall Instruments Div., Newton, CT) with a diamond knife (Du- 
Pont Co., Wilmington, DE). Sections for EM were mounted on 300-mesh 
grids, sections for EM autoradiography were lifted in a 3-mm Nichrome 
loop, and dried onto parlodian coated glass slides that were then carbon coated. 
Autoradiographic Method 
The light and EM level autoradiographic methods are essentially identical, 
except that Kodak NTB2 and Ilford L4 emulsions, respectively, were used. 
This resulted in individual silver grain sizes between 0.2 and 0.3/zm. 
The mounted slides were dipped in emulsion (1:10 dilution in water for 
EM,  1:1  dilution in water for light microscopy, 400C)  in total darkness, 
dried, and stored at 4°C. At varying times (<1 wk for light autoradiography, 
1-6 wk for EM level autoradiography), slides were developed (Ilford D19 
[light microscopy]), Microdol X [EM], 2 rain, 20"C); washed; fixed (4 rain 
Kodak rapid fix, 20°C); and prepared for microscopy. For light microscopy, 
sections were counter stained with buffered toluidine blue (0.1%) mounted 
in Permount (Fisher Scientific, Fair Lawn, N J) and cover slips were added. 
For EM, the method of Saltpeter and Bachmann (1972) was used. Sections 
were stripped from the slide in distilled water and dried onto grids; the 
mounting film was dissolved with butyl acetate and double stained with 2 % 
uranyl acetate (7 min) and 1% lead citrate (3 rain). All light-microscopic 
examinations were conducted with a Zeiss photomicroscope Ill. All EM- 
level examinations were carried out with a Philips EM 300. 
Quantitation of  AT Label in Cultures 
Qualitative observations show that the monolayer cultures of RFPEC cells 
cannot be treated as a random sample, since differentiation of cellular form 
is apparent throughout the macroscopic depth of the culture. Given that the 
size of  the culture is too great to sample completely by EM, it was necessary 
to select a region of cultured cells in which quantitation would prove most 
useful. To this end, samples were taken close to the dish surface, where AT 
labeling was most intense, cellular and matrix components were relatively 
random, and differentiation of cellular structure and label localization were 
easily analyzed. Furthermore, sections close to the dish surface showed de- 
velopment of an extensive array of surface-connected vesicles (SCV) which 
revealed a high degree of AT binding. 
A large number of micrographs (70) were taken at random from sections 
representative of monolayer cultures close to the dish surface, as well as 
from random sections through pellets of suspension cultures. The AT at- 
tachment to the extracellular matrix, SCV, cellular perimeter, and back- 
ground count in the free space were quantified by counting silver grains on 
micrographs and using a Microplan (Cambridge Instruments, Cambridge, 
MA) to measure the area of each compartment directly from the same 
micrograph. 
The number of silver grains in each compartment of the monolayer cul- 
ture was corrected for background by subtracting the count found in free 
space normalized for the area of the relevant compartment and then ex- 
pressed as a  percentage of the total number of labeling sites within the 
whole sectioned sample. 
In suspension culture the extent of  definable matrix and SCV is negligible 
(1.2 and 4.7 % of the area found in monolayer culture, respectively). Thus, 
no attempt was made to quantify binding in these cultures. However, the 
number of counts per unit length of cell perimeter was determined to com- 
pare the AT binding directly with that seen in the monolayer cultures. 
Results 
Binding of  AT to Endothelial Cells 
The binding of AT to various cell types was evaluated with 
~25I-labeled protease  inhibitor.  This  interaction  was  ob- 
served to be highly cell type related, as shown by the com- 
plexing of ~SI-AT with cell types known to synthesize an- 
ticoagulantly  active  heparan  sulfate  such  as  rat  fat-pad 
endothelial cells (RFPEC), but not with those only able to 
produce anticoagulantly inactive glycosaminoglycans such 
as Chinese hamster ovary cells or bovine smooth muscle 
cells (Table I). The binding of ~z~I-AT to RFPEC was dem- 
onstrated to be highly specific by competition studies using 
a  100-fold  molar  excess  of unlabeled  protease  inhibitor 
(defined as specific binding) (Table II). The complexing of 
radiolabelled protease inhibitor to RFPEC is due to inter- 
actions  with  anticoagulantly active heparan  sulfate since 
specific binding of 12~I-AT is greatly decreased by addition 
of soluble heparin but not by admixture of dextran sulfate, 
another sulfated macromolecule devoid of anticoagulant ac- 
tivity (Table II). Furthermore, the preincubation of RFPEC 
with purified Flavobacterium heparitinase for 1 h at 37°C 
dramatically  suppressed  AT  binding  (Table  II),  whereas 
treatment with chondroitinase ABC had no effect on this pa- 
rameter (data not shown). 
The  incubation  of increasing  concentrations  of 125I-AT 
Table L Cell Type Specificity of  AT Binding 
Cells  Bound at  % Binding 
cpm/50,O00 cells 
RFPEC  2,174  +  50  100 
Bovine smooth muscle cells  145  +  24  7 
CHO cells  53  +  7  2 
Cell monolayers were kept in culture for 14 days prior to the incubation with 
~25I-AT. ~2~I-AT (0.5-9.0 nM, 2  ×  10  ~ cpm/ml) was incubated for 1 h at 4°C 
on cell monolayers. 
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None 
AT (1 #M) 
Heparatinase (0.5 U/ml)  +  PMSF (0.1 raM) 
Heparin (I0 ~g/ml  =  1.7 U/ml) 
Dextran sulfate (10 ~g/ml) 
100 
28 
8 
2 
105 
90- 
teSI-AT (0.5-1.0  nM)  was incubated for  1 h  at 40C,  either alone or in the 
presence of cold AT, heparin, or dextran sulfate. Heparatinase was incubated 
on the cells for  1 h at 37°C before ~25I-AT was added. 
with RFPEC monolayer cultures revealed that the protease 
inhibitor binds  to this  cell type.  Under  our experimental 
conditions, the high-affinity binding sites for AT have a Kd 
of ~50 riM, a value comparable to that for heparin (Jordan 
et al.,  1982), and the number of binding sites per cell is of 
the order of 106 (Fig.  1). Note, however, that the saturation 
curve of AT binding to these monolayer cultures does not 
reach a true plateau,  indicating the presence of additional 
binding sites with much lower affinities for the protease in- 
hibitor. 
To ascertain whether AT bound to RFPEC is internalized, 
we examined the fate of radiolabeled protease inhibitor com- 
plexed to the above cell surface at 37°C. After 3 h of incuba- 
tion,  the  amount  of specifically  bound  ~2q-AT reached  a 
plateau at 3,880+/-  395 cpm/50,000 cells. The addition of 
a 100-fold molar excess of unlabeled AT at 2 h decreased the 
specific binding of radiolabeled protease inhibitor from 82 % 
at 2 h to 9% at 3 h, and 2% at 4 h. Similarly, the admixture 
of a  100-fold molar excess of unlabeled AT at 3 h reduced 
the specific binding of radiolabeled protease inhibitor from 
100% at 3 h to 11% at 4 h. These experiments indicate that 
significant amounts of AT are not internalized by RFPEC un- 
der the above conditions. 
We have also monitored the evolution of the AT binding 
80- 
iO- 
70- 
o  °  6o- 
o 
50- 
40- 
20- 
r  i  i  , 
,~0  I00  150  200 
1251 -AT (nM) 
Table II.  Specificity of nSI-AT Binding on RFPEC  ,*000. 
Figure  1.  Binding of ~25I-AT on RFPEC  monolayers.  Confluent 
monolayers grown for 8 d were incubated with various concentra- 
tions of 125I-AT (1.34  x  10  s cpndnmol),  as outlined in the text. 
Specific binding is calculated as the difference between binding in 
the presence and absence of a 100-fold molar excess of unlabeled 
AT. Specific nSI-AT  binding is plotted versus the molar concentra- 
tion of 125I-AT. 
32OO. 
24Oo 
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I- 
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confluence  DAYS IN CULTURE 
Figure  2.  Evolution  of ~25I-AT binding  on confluent  monolayer 
RFPEC cultures as a function of time in culture.  125I-AT  (0.5-1.0 
riM) was incubated as outlined in the text at different times after 
the cells reached confluence. The binding increases linearly up to 
16 d in culture. 
capacity of monolayer RFPEC cultures as a function of time 
in culture. A linear increase in the binding of protease inhibi- 
tor per cell with time in culture was noted (Fig. 2). The aug- 
mentation in this parameter could reflect either an accumula- 
tion of the anticoagulantly active HSPG on the cell surface 
or a constant secretion and accumulation of the biologically 
active proteoglycans in  the  extracellular matrix.  That the 
number of AT binding sites per cell increases linearly for up 
to 16 d in culture suggests a steady-state secretion of the an- 
ticoagulantly  active  proteoglycans  into  the  extracellular 
space. 
This  hypothesis  was  tested  by  establishing  suspension 
RFPEC  cultures  where  the  accumulation  of extraceUular 
matrix is minimized, and then determining the capacity of 
the above cells to bind AT as a function of time in suspension 
culture. The suspension RFPEC cultures were initially tryp- 
sinized to remove anticoagulantly active HSPG, which abol- 
ished the interaction with added ~2q-AT, and protease inhib- 
itor binding per cell was then measured as a function of time 
in culture (Fig. 3). The data show the reappearance of detect- 
able binding of ~25I-AT  after 1 h in culture with a peaking of 
complexed protease inhibitor per cell at 12 h. During the fol- 
lowing  12  h  in  culture,  the  binding  of  ~25I-AT per  cell 
diminishes to half of that observed with confluent monolayer 
cultures, and then remains constant for up to 5 d. Through- 
out  this  period  of time,  the  cells  remain  viable  and  go 
through at least one cycle of division. 
The appearance of anticoagulanfly active HSPG on the 
surface of RFPEC after short periods of time demonstrates 
the extremely rapid synthesis and/or transport of this specific 
proteoglycan. The decrease of AT binding per cell in suspen- 
sion cultures noted between 12 and 24 h after trypsin treat- 
ment may reflect the fact that synthesis and exposure of an- 
ticoagulantly active HSPG at the cell surface initially occurs 
more rapidly than its release to the media. Once the synthe- 
sis and release of anticoagulantly active HSPG appear to 
have attained steady state values, the AT binding capacity of 
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Figure 3. I~5I-AT  binding on RFPEC suspension cultures. 125I-AT 
(0.4 riM) was incubated with suspension RFPEC cultures for vari- 
ous times. After trypsin treatment (t =  0), ~25I-AT is rapidly re- 
stored, peaks at 12 h and stabilizes for 4 d. 
the  suspension  RFPEC  cultures  becomes  stable  for  a 
prolonged period of time in contrast to confluent monolayer 
RFPEC  cultures of the  same cell type.  This  observation 
could mean that anticoagulantly active HSPG do not ac- 
cumulate on the cell surface of confluent monolayer RFPEC 
cultures as a function of time in culture, but rather would be 
rapidly secreted and accumulated in the extracellular matrix. 
The above conclusion is based upon the assumption that the 
synthetic activity of suspension and  monolayer cells  are 
roughly equivalent. Therefore, we have attempted to localize 
AT binding sites by morphologic means in both confluent 
monolayer and suspension RFPEC cultures. This approach 
was taken to visualize anticoagulantly active HSPG on the 
cell surface and within the extracellular matrix, as well as 
to ascertain whether monolayer cultures accumulate HSPG 
on the cell surface to a greater extent than cells grown in sus- 
pension. 
Localization of  AT Binding to Cultured Endothelial 
Cells and Perfused Aorta 
125I-AT binds to RFPEC cultures, and its location may be 
ascertained by light-microscopic and EM level autoradiogra- 
phy.  2 The  light-microscopic examination of oblique  sec- 
tions through postconfluent monolayer cultures of RFPEC 
show clear differentiation of cell form. The cells nearest the 
dish surface are irregular in shape and often appear some- 
what stellate. Moving away from the dish surface, additional 
sections indicate that cells form whorls or hollow spheres 
(Fig. 4 A). Within whorls, free isodiametric cells with no ap- 
parent specialization are evident. In electron micrographs, 
the whorl structures, in which the outermost cells appear 
columnar in shape,  appear to be  surrounded by collagen 
fibrils. Basal lamina are noted between cells, and the colla- 
gen matrix (Fig. 4 B). It should be noted that given the ex- 
treme thinness of sections for EM (60-80 nm) sections may 
2. We have failed to detect AT bound to RFPEC with specific anti-AT anti- 
body populations. This observation suggests that antibody binding to the 
protease  inhibitor  destabilizes  the polysaccharide-protein  complex,  and 
thereby induces release of AT. 
pass over or under cells, which gives the appearance of sub- 
confluence. 
The above cultures were also studied by autoradiography 
at the light-microscopic level, which revealed a clear con- 
centration of labeling for AT around the whorl structures 
(Fig. 5 A). The labeled protease inhibitor was observed in 
increased amounts near the dish surface, but little or none 
is noted on cells in free space within the whorls.  Similar 
studies at the EM level support these observations. When 
fine details of the relative labeling within the cultures are 
resolved qualitatively, the morphological evidence indicates 
that labeled AT is particularly associated with basal lam- 
ina/basement membrane, as is clearly defined around the 
whorls (Fig. 5 B, and inset). When cells are cut immediately 
adjacent to the dish surface (below the nucleus), they show 
extensive vacuolation, which frequently appears to be con- 
netted to the cell surface, and to contain nondifferentiated 
filamentous material (SCV).  The material being extruded 
from the SCV vacuoles shows significant labeling for AT 
(Fig. 5 D). It is frequently possible to visualize matrix within 
SCV, which suggests that protease inhibitor binding may be 
due to complexing with these adhesive macromolecules. The 
entire cell perimeter is mainly free of label and associated 
matrix (Fig. 5 D). 
The suspension RFPEC cultures appear relatively homog- 
enous by light and EM,  showing none of the pattern of 
differentiation seen in the monolayer  cultures. The SCV were 
noted but were much less prominent (4.7%  of that found in 
the equivalent sampled area) than in the confluent monolayer 
RFPEC cultures. However,  some cells formed clusters, and 
extracellular matrix  is  present  at  the  cellular interfaces, 
which constitute the primary localization of 'zSI-AT (Fig. 5 
C).  Such matrix is rarely detectable, and only constitutes 
1.7 % of that formed in an equivalent area of monolayer cul- 
tures. 
Quantitation of  AT label in monolayer  cultures close to the 
dish surface defined the level of binding to the cell surface, 
to the extruded matrix outside the cells as well as within the 
SCV. It is clear that most (92%) of the count is associated 
with the extraceUular matrix and SCV and only 8 % may be 
attributed to the cell surface binding. This cell surface bind- 
ing is expressed in relation to the measured membrane pe- 
rimeter in the cell monolayer (0.03 silver grain per/~m) as 
compared with the surface of suspension cells (0.006 silver 
grains per #m). The amount of count on the membrane of 
monolayer cultures is thus calculated to be five times that 
seen on suspension cultures labeled under the same condi- 
tions. This observation may be due to the different  conditions 
under which monolayer and suspension cultures are main- 
tained or to the close apposition of monolayer but not sus- 
pension cultures to the dish surface where secreted HSPG 
can be trapped. 
The total area of SCV in monolayer cells constitutes 5 % 
of the scored cellular area (2.5 % total culture area exam- 
ined) but contains 43 % of the count, presumably due to the 
AT binding capacity of the newly secreted HSPG which is 
partially retained in that compartment. This possibility is 
reinforced by the fact that heavily labeled matrix components 
are frequently definable within the SCV. 
The extracellular matrix binds 48 % of the labeled AT, al- 
though it constitutes only 6.2% of the total culture area. It 
should be noted that it is difficult to define the limits of the 
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tinuous nature, so that we estimate that the figure of 6.2% 
is high, possibly by as much as an order of  magnitude. While 
it was not possible to derive quantitative figures for matrix 
binding in suspension cells due to its relative paucity, when 
matrix was apparent, labeling was intense in this compart- 
ment (Fig. 5 C). A control was executed to ensure that the 
labeling was specific and not due to non-specific trapping of 
AT. To this end cultures were incubated with a 100-fold ex- 
cess of cold AT, which effectively removed all labeling. 
We also attempted to visualize the in vivo position of an- 
ticoagulantly active HSPG by perfusing normal and dam- 
aged rat aorta for 1 to 3 h with 125I-AT, and then determin- 
ing the specific localization of labeled protease inhibitor as 
outlined above.  The duration of perfusion had no obvious 
quantitative effect on the extent of labeling observed. Thus, 
the saturation of specific binding sites with labeled protease 
inhibitor probably occurs in <1 h. It is readily apparent that 
t25I-AT is bound to the aortic subendothelium. This finding 
is particularly evident with light microscopy, which shows 
that only small quantities of labeled protease inhibitor are 
found within the smooth muscle or connective tissue of the 
aorta, or bound to the luminal side of the endothelium (Fig. 
6 A). This localization of AT binding is more clearly defined 
at the EM level, which demonstrates that labeled protease in- 
hibitor is clearly present beneath the endothelial cells (Fig. 
6 B). Quantitation of the above data reveal that <1% of the 
bound ~2q-AT is associated with the luminal face of the en- 
dothelium, which is just above background values. For ex- 
ample, only 3 luminal counts were present in an experiment, 
versus 530 abluminal counts. The labeled protease inhibitor 
is also noted to bind in regions around small capillaries, pe- 
ripheral  to  the  aortic  muscle  layer.  This  observation  is 
clearly depicted at the light microscopic level (Fig. 6 C), but 
the position of the ~2q-AT is best defined at the EM level to 
be in the subendothelium, associated with the basal lam- 
ina/basement membrane rather than collagen fibers (Fig. 6 
D).  The above experiment was repeated by perfusing the 
aorta with ~2q-BSA, which produced no detectable labeling 
in any locale. This latter observation demonstrates that the 
binding of 125I-AT within the aorta is not caused by non- 
specific interactions or trapping of labeled protease inhibi- 
tor.  To  ensure  that the  125I-AT interacts  specifically with 
HSPG, the vasculature was perfused with Flavobacterium 
heparitinase before perfusion with ~25I-AT. This treatment 
effectively prevented any binding of the labeled inhibitor to 
all regions of the tissue including the subendothelium, and 
left the endothelial layer intact. 
We finally tried to mimic vascular injury by crushing the 
aorta before perfusion with  ~2q-AT, and then determined 
the position of the labeled protease inhibitor following tissue 
damage. The above manipulation dramatically altered the 
morphology and pattern of tissue labeling. The loss of en- 
dothelial cells was consistently evident, and light autoradi- 
ography showed an extremely intense concentration of 12q_ 
AT apparently bound to the subendothelium. In the damaged 
aorta, the labeled protease inhibitor appeared as a solid line 
of dense silver (Fig. 6 E), whereas in the normal blood ves- 
sel, the ~Zq-AT is bound in particulate form. The EM level 
autoradiography revealed an increased accumulation of 125I- 
AT in the subendothelium with bound protease inhibitor also 
associated with capillaries, aortic muscular wall connective 
tissue,  and  extra-aortic  connective  tissue.  The  extensive 
complexing of mI-AT with the subendothelial layer in the 
damaged aorta suggests that the low level of label on the lu- 
minal face of endothelial cells in the normal vessel is not 
caused by a  shearing effect of the perfusate on the bound 
protein. 
Discussion 
Endothelial cell HSPG are members of the family of  cell sur- 
face  and  extracellular  matrix  proteoglycans.  In  general, 
HSPG are either inserted into the cell membrane via a core 
protein hydrophobic domain or glycolipid anchor, loosely 
bound to the cell surface via interactions with glycosamino- 
glycan sidechains, or localized within the extracellular ma- 
trix because of complexing to collagen, fibronectin, laminin 
and other structural glycoproteins (Hayman et al.,  1982; 
Hook et al.,  1984;  Fransson et al.,  1986;  Ishibara et al., 
1987). The cell surface associated and matrix associated pro- 
teoglycans have no discernible core protein hydrophobic do- 
mains, and are readily displaceable from the cell surface with 
heparin. Cells synthesize HSPG whose hydrophobic domains 
may be variably cleaved by a specific plasmalemmal protease 
which allows the proteoglycan to become associated with the 
cell surface or the extracellular matrix (Brandan et al., 1989). 
Alternatively, cells also produce secretory HSPG with no 
hydrophobic domains which may be relatively resistant to 
the action of pronase and accumulate predominantly in the 
basement membrane (Oohira et al., 1983; Pejler et al., 1987). 
The present investigation was initiated to define the posi- 
tion of anticoagulantly active HSPG on cultured endothelial 
cells as well as whole aortic preparations. This unique subset 
of HSPG bear carbohydrate chains with regions of defined 
monosaccharide sequence. Previous investigations summa- 
rized in the Introduction suggest that anticoagulantly active 
HSPG are produced by endothelial cells and are able to inter- 
act with blood AT (Marcum et al.,  1986a,b;  Stern et al., 
1985).  The localization of this specific subset of proteogly- 
cans  was  attempted by visualizing the binding of ~25I-AT 
with light and EMs level autoradiography. The first pub- 
lished studies to pinpoint the position of vessel wall HSPGs 
were reported by Simonescu and coworkers (Simonescu et 
al., 1981). These investigators used in vivo and in situ bind- 
ing  of cationic  ferritin  which  could  be  eliminated with 
Flavobacterium heparinase to demonstrate by EM that the 
various classes of HSPG were concentrated on the fenestral 
diaphragms, and, to a much smaller extent, luminal plas- 
malemma  of visceral  capillary  endothelium.  Subsequent 
Figure 4. Light and electron micrographs of monolayer RFPEC cultures. (A) Light micrograph of confluent RFPEC monolayer cultures 
thin sections (0.5/~m) suggesting  that three-dimensional  whorls of cells (as demarcated by lines) are clearly present. Bar, I0 #m. (B) Elec- 
tron micrograph of whorl structure seen in A. Endothelial cells with columnar shape line the lumen, around which some pseudopodia 
are evident (open arrow).  Collagen fibers (closed arrows)  are associated with the basal layer. Bar, 1 gm. 
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(Clowes et al.,  1984;  Hatton et al.,  1988). 
We  initially used  a  direct binding  assay  for  z2~I-AT, in 
conjunction with  a  pretreatment  with  purified Flavobac- 
terium heparinase,  to establish the presence of anticoagu- 
lantly active HSPG on the surface of cloned confluent mono- 
layer RFPEC cultures. The results obtained are in excellent 
agreement with prior data which show that heparan sulfates 
isolated from the same cells accelerate thrombin-AT interac- 
tions as well as possess the critical monosaccharide sequence 
to bind protease inhibitor (Marcum et al., 1985). We subse- 
quently measured the  amount of AT bound by confluent 
monolayer RFPEC cultures as a function of time in culture, 
and showed that the number of protease inhibitor binding 
sites per cell increase in a linear manner for at least 16 d. 
Marcum et al. have observed a similar time dependent aug- 
mentation in the anticoagulant activity and cell surface hepa- 
ran sulfates (Marcum et al.,  1986a; Marcum, J., personal 
communication). These data suggest that the anticoagulantly 
active HSPG synthesized by endothelial ceils may be secreted 
into the extracellular matrix where they accumulate in sub- 
stantial amounts.  This possibility was tested by examining 
the behavior of suspension cultures of the same rodent mi- 
crovascular endothelial cells which would have little oppor- 
tunity to develop an elaborate extracellular matrix.  Under 
these conditions, RFPEC did not exhibit any time dependent 
accumulation of radiolabeled protease inhibitor binding sites. 
The above results prompted us to visualize the location of 
~25I-AT binding  to  confluent  monolayer  and  suspension 
RFPEC cultures using both light and EM level autoradiogra- 
phy. In all cases cited, the binding of labeled AT was judged 
to be specific since it could not be duplicated with radiola- 
beled BSA but could be competed with unlabeled protease 
inhibitor. The extracellular matrix of  RFPEC is defined mor- 
phologically as basement membranes which surround whorls 
or hollow spheres of cells; collagen fibrils, which are seen 
about the whorls; and a poorly defined matrix within SCV, 
and at the surface of the plastic culture dish. The most obvi- 
ous subcellular compartments of monolayer cultures that la- 
bel positively for AT are extracellular matrix associated with 
the basement membrane. The binding of radiolabeled pro- 
tease inhibitor is also abundant in the matrix contained with- 
in or extruded from SCV. It is of interest to note that other 
investigators have observed that basement membrane con- 
tain heparan sulfate (Hay, 1981; Hedman et al., 1982). There- 
fore, it is not surprising that the anticoagulantly active HSPG 
are preferentially found within these locales. By contrast, lit- 
tle AT binding is observed on the suspension RFPEC, where 
the predominant labeling detected occurs at the occasional 
junction of two cells that may possess small amounts of ex- 
tracellular matrix. In confluent monolayer RFPEC culture 
"~8%  of the  125I-AT is associated with the cell surface. In 
suspension RFPEC cultures only ,,,,1.7  % of the radiolabelled 
protease inhibitor is complexed with this region. 
We note with interest that the above estimate of  ceil surface 
anticoagulantly active HSPG is in reasonable accord with re- 
cent biochemical data collected by us for RFPEC. The. ro- 
dent microvascular endothelial cells in monolayer culture 
have been radiolabeled for 24 h with 35S, and HSPG have 
been  isolated  from  the  cells  and  surrounding  matrix  by 
column separation techniques including AT affinity chroma- 
tography (unpublished data). The results indicate that only 
"~5-7%  of the anticoagulantly active HSPG are endowed 
with hydrophobic domains as judged by retention on octyl- 
Sepharose,  but  that  both  types  of anticoagulantly  active 
HSPG species possess similar structures as judged by the 
molecular sizes and peptide maps of the core proteins (pre- 
liminary  results).  Given  that  the  anticoagulantly  active 
HSPG with no hydrophobic domains would be expected to 
continuously accumulate within extracellular matrix as the 
anticoagulantly active HSPG with hydrophobic domains is 
degraded, it is not surprising that only a small percentage of 
the AT binding sites synthesized over an 8-d period would 
constitute an integral component of the cell membrane. 
To visualize the in vivo location of the anticoagulantly ac- 
tive HSPG, we perfused rat aorta with '25I-AT, and then de- 
termined  the  position  of radiolabeled  protease  inhibitor 
binding sites as outlined above. The data revealed a highly 
significant interaction of '25I-AT with  the aortic and vasa 
vasorum (microvascular) endothelial cell basement mem- 
branes, with only small amounts of protease inhibitor bind- 
ing observed on the luminal surface of endothelial cells or 
in the surrounding smooth muscle cell connective tissues. 
Based upon the above data, we suggest that the overlying en- 
dothelial cells  produce anticoagulantly active HSPG,  the 
proteoglycans are initially positioned within the cell mem- 
branes due to their hydrophobic domains, the protein cores 
are then cleaved by the plasmalemmal  proteases and the 
liberated macromolecules accumulate within the extracellu- 
lar  matrix.  Alternately,  we  might  hypothesize  that  en- 
dothelial cells synthesize a class of secretory anticoagulantly 
active HSPG that might also accumulate predominantly in 
the basement membrane.  Indeed,  this  latter type of pro- 
teoglycan has been isolated from Reichert's membrane, and 
is structurally similar to the heparin proteoglycan in that it 
is resistant to cleavage by pronase (Pejler et al.,  1987). The 
two models are consistent with the known synthesis of an- 
ticoagulantly active HSPG by cultured endothelial cells and 
anticoagulantly inactive HSPG by cultured smooth muscle 
cells as well as the previous isolation of anticoagulantly ac- 
tive HSPG from aortic intima and anticoagulantly inactive 
HSPG from aortic media (Marcum and Rosenberg,  1984). 
Figure 5. Light and EM level autoradiographs of confluent monolayer and suspension RFPEC cultures. (A) Light microscopic autoradio- 
graphs of a'I-AT in which grains clearly delineate the periphery of whorl structures (arrows) in the basal layer. Bar, 10 #m. (B) Electron 
microscopic autoradiographs of interstitial collagen fibrils within confluent monolayer RFPEC culture showing a high density of label ap- 
parently associated with the obliquely cut basal lamina (arrows). Bar, 1 #m. (Inset) Area selected to show abundantly labeled, tangentially 
cut basal lamina (arrows) associated with the cell surface. Bar, 1 #m.  (C) Matrix labeling of ~25I-AT is mainly observed at the cell-cell 
interfaces of the suspension RFPEC cultures. Bar, 1 #m. (D) A cell from a monolayer RFPEC culture cut below the nucleus near the 
dish surface. Extensive 12~I-AT labeling is seen within the surface connected vesicles, which are shown to contain extracellular matrix 
(arrow).  Bar,  1 #m. 
de Agostini et al. Endothelial Cell Anticoagulant Heparan Sulfate  1301 Figure 6. Light and electron micrographs as well as light and EM level autoradiographs of perfused normal and damaged rat aorta. (A) 
Light microscopic autoradiograph of rat aorta after perfusion with 125I-AT. The intense labeling is noted in the basement membrane be- 
neath the endothelial cells (arrows).  Bar,  10 #m.  (B) EM level autoradiograph of rat aorta after perfusion with t25I-AT. The labeling is 
clearly evident beneath the endothelial cells. Bar, 1.0 #m. (C) Light microscopic autoradiograph of rat aorta after perfusion with ~5I-AT. 
The intense labeling is noted around the small capillaries within the adjacent microcirculation, in association with the basal lamina and 
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tive tissue could be due to the production  of anticoagulantly 
active HSPG by fibroblasts  (Marcum et al.,  1986b). 
The  above  localization  of anticoagulantly  active  HSPG 
suggests that previous studies which measured the extent of 
AT binding to glycosaminoglycans  of cultured endothelial 
cells or aortic explants need to be reinterpreted  (Stem et al., 
1985;  Marcum et al.,  1986a).  It would appear that the de- 
gree  of AT  binding  per  cell  reflects  not  only  the  small 
amounts of cell surface anticoagulantly active HSPG but also 
access to the much larger quantities  of the same material on 
the basolateral surface of these cells. Schleef and co-workers 
(Schleef et al.,  1990)  have  reported a similar situation  for 
type 1 plasminogen activator inhibitor, which is mainly pres- 
ent on the basolateral surface of human umbilical vein en- 
dothelial cells, but is accessible to exogenously added tissue 
type plasminogen activator. 
Two possible scenarios can be constructed whereby an- 
ticoagulantly  active HSPG might regulate the coagulation 
cascade. On the one hand, the small amounts of luminal an- 
ticoagulantly active HSPG could be critically placed to bind 
plasma AT, accelerate the action of the protease inhibitor, 
and thereby  regulate hemostatic mechanism activity at the 
blood-vessel  wall interface.  The much larger  quantities  of 
abluminal  anticoagulantly  active  HSPG  would serve  as  a 
potential reservoir that could be brought into play with ex- 
tensive damage to the overlying endothelium. On the other 
hand, the substantial  amounts of the anticoagulantly active 
HSPG that  accumulate  on the abluminal  surface of endo- 
thelial cells could also act to modulate the ambient function 
of the coagulation cascade. Plasma AT should have relatively 
free access to this locale as suggested by numerous studies 
which document the extraordinary  permeability of the en- 
dothelial cell layer (Simonescu,  1983). The presence of this 
subendothelial  concentration  of anticoagulantly  active HSPG 
would also explain kinetic radiotracer  studies that  suggest 
that a significant amount of labeled protease inhibitor is lo- 
cated  in  a  unique  extravascular  compartment  (Carlson  et 
al., 1985). The interaction of coagulation enzymes with AT 
bound to subendothelial anticoagulanfly active HSPG could 
constitute  the  heparin-like,  macromolecule-dependent  ac- 
celeration of protease inhibitor action observed in animal 
models outlined above. This would imply that inhibition of 
coagulation  enzymes  is quite active within subendothelial 
regions, and would expand our present notions of the critical 
biologic surfaces which are in contact with the hemostatic 
mechanism. It seems quite likely that both scenarios outlined 
above could be functional under in vivo conditions. 
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